Articles & Whitepapers
For a long time, the research and development of each new drug has faced the challenges of high cost and long cycle. In response to these challenges, major pharmaceutical companies have shifted from targeting common diseases to developing drugs for specific diseases. At the same time, these companies are constantly looking for new technologies for new drug development, such as high-throughput ...
Proteolysis Targeting Chimeras (PROTACs) are a novel approach for degrading target proteins. Recently, a new split-and-mix PROTAC (SM-PROTAC) system based on liposome self-assembly, known as ...
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the ...
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
Equipment & Solutions
The BIP ETT is used to secure an open airway during anesthesia or when intubation is necessary as part of standard medical care. It is inserted through the mouth or nose into the trachea and connected to a ventilator.
PDA is thrilled to present an exclusive opportunity for you to enhance your professional skills and expertise, immerse yourself in the latest technologies and practices, and broaden your perspectives at the inaugural PDA Week, taking place in Long Beach, CA. At the core of PDA Week is the reimagined 2024 PDA Annual Meeting. It has been revamped and rejuvenated with our members in mind, offering ...